When HIV/AIDS began devastating Kenya in the late 1980s and early 1990s, the disease carried fear, stigma and a sense of helplessness.
There were limited treatment options, and a locally developed medicine claiming to reverse the effects of HIV quickly captured national attention.
At the centre of that extraordinary episode was Kenyan medical scientist Prof Arthur Obel, whose name became inseparable from the controversial HIV/AIDS treatments Kemron and later Pearl Omega.
His work generated excitement among desperate patients but also intense criticism from scientists who questioned whether the medicines had been subjected to sufficiently rigorous clinical testing.
Kemron was based on low-dose alpha interferon, a substance involved in the body's immune response. Early reports from Kenya suggested that patients receiving the treatment experienced improvements in their health, and some claims went further, suggesting that the drug could eliminate HIV from patients' blood.
Those claims created enormous public interest. At a time when HIV treatment was largely inaccessible to many Kenyans, the possibility that a Kenyan scientist had discovered an affordable treatment offered hope to thousands of families.
The excitement also attracted political attention. The Kenyan government supported research around Kemron, while then-President Daniel arap Moi publicly backed the treatment. The drug became a symbol of the country's hopes of producing its own answer to the AIDS crisis.
But the claims soon faced a major scientific test.
International researchers sought to determine whether the apparent benefits reported in Kenya could be reproduced under controlled conditions. A World Health Organization-supported multicountry study involving patients in several African countries failed to reproduce the earlier results. Contemporary accounts describe the WHO findings as inconclusive and unable to replicate the benefits reported by the Kenyan researchers.
That development dealt a major blow to Kemron's reputation. The treatment did not establish itself as an effective cure for HIV/AIDS, despite the hopes that had surrounded it.
Obel, however, did not abandon his search for a solution.
He later became associated with Pearl Omega, another treatment that he claimed could help people living with HIV/AIDS. The claims surrounding Pearl Omega were again dramatic, with Obel reporting that some patients had experienced major improvements and that the treatment could affect their HIV status.
The controversy intensified because questions were raised about the scientific evidence supporting those claims and whether the treatment had received the necessary regulatory approval. In 1996, medical literature reported that patients had sued Obel in connection with the treatments, while Pearl Omega had been banned by Kenya's Ministry of Health.
The dispute was not simply scientific. It became a question of medical ethics, regulation and the responsibility of researchers dealing with desperate patients.
For people living with AIDS at the time, the promise of a cure was powerful. Many patients were willing to try treatments that offered even a possibility of improvement. But critics argued that extraordinary medical claims required equally strong scientific evidence before treatments could be promoted to vulnerable patients.
Obel nevertheless maintained his interest in HIV research for years. His supporters viewed him as a pioneering African scientist attempting to find affordable solutions to a devastating epidemic, while his critics regarded the Kemron and Pearl Omega episodes as cautionary examples of what could happen when medical claims move faster than scientific evidence.
The controversy ultimately overshadowed much of his wider career in medicine and research. Obel had trained extensively in therapeutics and clinical medicine and worked in senior research and government positions.
He died in Nairobi on September 27, 2025, aged 76, bringing an end to the life of a scientist whose name remains firmly linked to one of Kenya's most contentious chapters in the history of HIV/AIDS treatment.
More than three decades later, the Kemron episode remains a reminder of the enormous desperation surrounding the early HIV/AIDS epidemic—and of the difficult line between scientific innovation, public hope and evidence-based medicine.